Pfizer - About the company
Pfizer is a public company based in New York City (United States), founded in 1849 by Charles Pfizer and Charles Erhart. It operates as a Provider of pharmaceutical products for multiple disease treatments. Pfizer has raised an undisclosed amount in funding. The company has 1446 active competitors, including 76 funded and 187 that have exited. Its top competitors include companies like AbbVie, Amgen and Gilead.
Company Details
Provider of pharmaceutical products for multiple disease treatments. It has developed a novel cancer medicine that works by inhibiting blood supply in tumor cells and destroys cellular reproduction. The other product includes Chantix that helps smokers to quit smoking.In 2022, the company recorded annual revenues of $92.95B and a net profit of $29.04B.
- Website
- www.pfizer.com/
- Phone Number
- +1 **********
- Registered Address
- Peapack, New Jersey
Key Metrics
Founded Year
1849
Location
New York City, United States
Stage
Public
Latest Funding Round
Investors
Ranked
13th among 1446 active competitors
Annual Revenue
$1B+ as on Dec 31, 2025
Employee Count
102,894 as on Mar 31, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Pfizer
Pfizer is associated with 11 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
PFIZER LIMITED CIN: L24231MH1950PLC008311 , India, Active | Nov 21, 1950 | ₹1,000+ Cr (As on Mar 31, 2025) | 1711 (As on Feb 29, 2024) | |
PFIZER INC CIN: 0713.748.368 , Belgium, Active | Aug 01, 2018 | €1B+ (As on Dec 31, 2023) | - | - |
Pfizer Inc CIN: 135315170 , United States, Active | Dec 26, 999 | $1B+ (As on Dec 31, 2025) | 29469 (As on Dec 31, 2024) | - |
PFIZER PRODUCTS INDIA PRIVATE LIMITED CIN: U24230MH1996FTC148003 , India, Active | Dec 19, 1996 | ₹500 - ₹1,000 Cr (As on Mar 31, 2025) | 399 (As on Aug 01, 2025) | |
WATSON PHARMA PRIVATE LIMITED CIN: U24230MH2005PTC156968 , India, Active | Oct 21, 2005 | ₹1,000+ Cr (As on Mar 31, 2025) | 1035 (As on Mar 31, 2024) | |
Trillium Therapeutics Inc. CIN: 1616212 , United States, Active | Mar 25, 2015 | $0 - $1M (As on Dec 31, 2020) | - | - |
PFIZER HEALTHCARE INDIA PRIVATE LIMITED CIN: U24232TN2009PTC073563 , India, Active | Nov 17, 2009 | ₹1,000+ Cr (As on Mar 31, 2025) | 2457 (As on Feb 29, 2024) | |
Pfizer Export B.V. CIN: 26397472429 , Croatia, Active | Jun 26, 2017 | $1M - $10M (As on Nov 30, 2018) | - | |
PFIZER PHARMACEUTICALS LLC CIN: 660577291 , United States, Active | Dec 31, 1999 | - | 1362 (As on Dec 31, 2024) | - |
PFIZER (THAILAND) COMPANY LIMITED CIN: 0105511004048 , Thailand, Active | Aug 16, 1968 | $100M - $500M (As on Dec 31, 2023) | - | |
PFIZER AS CIN: 915213596 , Norway, Active | Nov 24, 1959 | - | 108 (As on Dec 31, 2022) |
Pfizer's IPO details
Pfizer got listed on Dec 21, 1984.
Click here to take a look at Pfizer's IPO in detail
Sign up to download Pfizer's company profile
Pfizer's funding and investors
Pfizer has raised funding over 11 rounds. Its first funding round was on Jun 02, 2009. Its latest funding round was a Grant (prize money) round on Jun 27, 2023 for $*****. 1 investor participated in its latest round. Pfizer has 18 institutional investors.
Here is the list of recent funding rounds of Pfizer:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 27, 2023 | 6027785 | Grant (prize money) | 3387585 | 9675203 | 9561871 | 3649182 |
Jan 01, 2020 | 3948866 | Grant (prize money) | 6087651 | 9466525 | 6777922 | |
Sep 2018 | 7794362 | Conventional Debt | 2423744 | 5962162 | 1129896 | 2593907 |
View details of Pfizer's funding rounds and investors
Pfizer's founders and board of directors
Founder? Claim ProfileThe founders of Pfizer are Charles Pfizer and Charles Erhart.
Here are the details of Pfizer's key team members:
- Charles Pfizer: Former Co-Founder of Pfizer and founder of 1 other company.
- Charles Erhart: Former Co-Founder of Pfizer and founder of 1 other company.
- Albert Bourla: CEO of Pfizer.
View details of Pfizer's Founder profiles and Board Members
Pfizer's employee count trend
Pfizer has 102,894 employees as of Mar 26. Here is Pfizer's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Pfizer's Competitors and alternates
Top competitors of Pfizer include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Pfizer, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
2nd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 81/100 | |
3rd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 80/100 | |
4th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 79/100 | |
5th | Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
6th | AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 73/100 | |
7th | Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
8th | ![]() Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 71/100 | |
9th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
10th | Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 | |
13th | Pfizer 1849, New York City (United States), Public | Provider of pharmaceutical products for multiple disease treatments | - | 68/100 |
Looking for more details on Pfizer's competitors? Click here to see the top ones
Pfizer's Investments and acquisitions
Pfizer has made 161 investments in companies including STORM Therapeutics and Crossbow. Pfizer has also acquired 37 companies including Metsera and Seattle Genetics.Here is the list of investments & acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Apr 16, 2026 | Investments | 2015 | Waterbeach (United Kingdom) | |
Mar 18, 2026 | Investments | 2021 | Cambridge (United States) | |
Jan 08, 2026 | Investments | 2025 | Paris (France) |
See all investments and acquisitions by Pfizer
Reports related to Pfizer
Here is the latest report on Pfizer's geography:
News related to Pfizer
Media has covered Pfizer for a total of 389 events in the last 1 year, 216 of them have been about company updates and 20 about partnerships.
•
Leads Biolabs Partner Oblenio Bio Secures $62 Million Series B Financing for Autoimmune Disease Drug LBL-051GlobeNewswire•Jun 25, 2026•Nanjing Wei Li Zhi Bo Biotechnology, Pfizer, Aditum Bio, Deep Track Capital and 1 other
•
•
Pfizer's investigational lung cancer drug shows mixed results in Phase 3 trialBioSpace•Jun 23, 2026•Pfizer
•
Pfizer and Johnson & Johnson: Pillars of Passive Income in HealthcareWall St.•Jun 21, 2026•Pfizer, Johnson & Johnson
•
UK Regulator Wins Decade-Long Pricing Dispute with PfizerCity A.M.•Jun 19, 2026•Pfizer, Flynn Pharma
•
•
Gero Secures $34M in Equity Funding to Develop Medicines for AgingTMC•Jun 17, 2026•Gero, Melnichek Investments, Human Longevity, Pfizer and 2 others
•
•
Pfizer's Hympavzi Secures FDA Expanded Indications for HemophiliaHospital Management•Jun 09, 2026•Pfizer
•
Pfizer Reports Positive Phase IIb Trial Results for Berobenatide, a Potential Monthly GLP-1 RA Peptide for Obesityclinicaltrialsarena.com•Jun 08, 2026•Pfizer
Are you a Founder ?
FAQs about Pfizer
Explore our recently published companies
